NPI: 1205488996 · PENNINGTON GAP, VA 24277 · Critical Access Hospital · NPI assigned 07/12/2019
Authorized official HILTON, SHANE controls 20+ related entities in our dataset. Read more
| Authorized Official | HILTON, SHANE (EVP/CFO) |
| NPI Enumeration Date | 07/12/2019 |
Other providers sharing the same authorized official: HILTON, SHANE
| Year | Claims | Total Paid |
|---|---|---|
| 2021 | 13,572 | $667K |
| 2022 | 35,131 | $2.18M |
| 2023 | 35,394 | $2.97M |
| 2024 | 27,180 | $2.46M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | 11,954 | 10,760 | $2.97M | |
| 99283 | 6,431 | 5,844 | $1.41M | |
| 99285 | 3,431 | 3,060 | $844K | |
| 96361 | 1,721 | 1,460 | $632K | |
| 0241U | 5,793 | 5,390 | $472K | |
| 99282 | 1,883 | 1,755 | $382K | |
| 70450 | 1,179 | 1,082 | $342K | |
| 74176 | 989 | 924 | $271K | |
| 74177 | 925 | 868 | $239K | |
| 80307 | 1,171 | 1,063 | $118K | |
| 96365 | 966 | 882 | $87K | |
| 99291 | 200 | 182 | $62K | |
| 71275 | 175 | 161 | $57K | |
| 96366 | 161 | 127 | $49K | |
| 93306 | 77 | 76 | $45K | |
| 94640 | 995 | 894 | $33K | |
| 80053 | 6,092 | 5,220 | $26K | |
| 71046 | 1,776 | 1,680 | $25K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,706 | 1,573 | $24K |
| 96360 | 136 | 130 | $22K | |
| 93005 | 3,867 | 3,206 | $14K | |
| 87651 | 2,622 | 2,465 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 623 | 560 | $8K |
| 71045 | 2,679 | 2,392 | $8K | |
| 83880 | 847 | 760 | $8K | |
| 87040 | 1,743 | 889 | $7K | |
| 96374 | 3,157 | 2,827 | $7K | |
| 85025 | 6,737 | 5,697 | $7K | |
| 36415 | 2,091 | 1,850 | $5K | |
| 81025 | 1,328 | 1,230 | $5K | |
| 96375 | 2,539 | 2,110 | $5K | |
| 73562 | 303 | 291 | $5K | |
| 80048 | 1,479 | 1,299 | $5K | |
| 72100 | 153 | 147 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 14 | 14 | $4K |
| 73630 | 425 | 396 | $4K | |
| 72125 | 85 | 78 | $4K | |
| 84443 | 516 | 493 | $4K | |
| 81001 | 2,622 | 2,373 | $3K | |
| 96372 | 2,170 | 1,962 | $3K | |
| 90715 | 98 | 93 | $3K | |
| 74018 | 109 | 106 | $3K | |
| 76705 | 27 | 24 | $2K | |
| 85379 | 727 | 682 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 115 | 112 | $2K |
| 84484 | 2,792 | 2,194 | $2K | |
| 96376 | 772 | 606 | $2K | |
| 73130 | 184 | 176 | $2K | |
| 81003 | 1,852 | 1,697 | $2K | |
| 87635 | 128 | 119 | $2K | |
| 73610 | 248 | 230 | $2K | |
| 73030 | 106 | 101 | $1K | |
| 83735 | 1,353 | 1,147 | $1K | |
| 73110 | 84 | 78 | $923.40 | |
| 0202U | 86 | 85 | $816.52 | |
| 74022 | 114 | 108 | $811.09 | |
| 80143 | 159 | 143 | $772.82 | |
| 85027 | 677 | 623 | $751.78 | |
| 71250 | 15 | 15 | $743.62 | |
| 83605 | 1,473 | 1,059 | $733.65 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,672 | 1,438 | $715.69 |
| 83690 | 1,951 | 1,763 | $705.37 | |
| 94760 | 908 | 803 | $688.74 | |
| 87086 | 943 | 860 | $668.17 | |
| 90471 | 128 | 107 | $594.46 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,214 | 1,044 | $541.09 |
| 80179 | 158 | 143 | $532.63 | |
| 36600 | 166 | 145 | $450.66 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,328 | 1,174 | $384.64 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 564 | 457 | $355.63 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,807 | 1,636 | $339.79 |
| 80061 | 43 | 40 | $334.37 | |
| 87186 | 341 | 304 | $288.19 | |
| 82805 | 52 | 46 | $280.49 | |
| 85610 | 389 | 348 | $239.63 | |
| 87077 | 316 | 292 | $197.23 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 178 | 135 | $176.58 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 97 | 77 | $165.10 |
| 87880 | 993 | 935 | $155.55 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 187 | 175 | $153.28 |
| 83036 | 32 | 29 | $138.23 | |
| 82803 | 222 | 143 | $93.24 | |
| 87081 | 930 | 874 | $80.53 | |
| 87804 | 746 | 352 | $54.48 | |
| 82375 | 52 | 46 | $53.66 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 41 | 40 | $51.31 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 38 | 34 | $50.43 |
| 84703 | 73 | 68 | $34.63 | |
| J2060 | Injection, lorazepam, 2 mg | 96 | 80 | $32.95 |
| 83050 | 52 | 46 | $31.35 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 80 | 76 | $27.66 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 355 | 343 | $22.34 |
| 84439 | 12 | 12 | $18.26 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 78 | 72 | $4.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 57 | 46 | $1.92 |
| J1940 | Injection, furosemide, up to 20 mg | 17 | 12 | $1.20 |
| J1815 | Injection, insulin, per 5 units | 23 | 12 | $0.48 |
| 87811 | 14 | 13 | $0.00 | |
| 85007 | 14 | 14 | $0.00 | |
| 87205 | 15 | 12 | $0.00 | |
| 87070 | 15 | 12 | $0.00 |